ArticleThe Pan African medical journal2025
Association of angiotensin-converting enzyme gene insertion/deletion polymorphism (rs4646994) with schizophrenia in an eastern Algerian population: a case-control study.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: the Angiotensin-Converting Enzyme (ACE) is a critical enzyme in the renin-angiotensin system and influences neurotransmitter regulation, including dopamine. Previous studies have suggested a potential association between ACE gene polymorphisms and psychiatric disorders, including schizophrenia. This study aimed to investigate the association between the insertion/deletion (I/D) polymorphism in the ACE gene and schizophrenia in an Eastern Algerian population. Methods: a case-control study was conducted involving 157 schizophrenia patients and 222 healthy controls. Deoxyribonucleic acid (DNA) was extracted from peripheral blood using the salting-out method, and the ACE I/D polymorphism was genotyped using the polymerase chain reaction (PCR) technique. Statistical analyses were performed using SPSS version 26.0. Results: no significant association was observed between the ACE I/D polymorphism and schizophrenia. Compared to the DD genotype, the ID genotype showed OR = 0.84 (95% CI: 0.47-1.50, P = 0.66), and the II genotype OR = 0.47 (95% CI: 0.05-4.54, P = 0.66). The I allele was also not significantly associated (OR = 0.80, 95% CI: 0.47-1.33, P = 0.38). Dominant, over-dominant, and recessive models showed no significant results. Conclusion: these findings suggest that the ACE I/D polymorphism does not contribute to the genetic susceptibility to schizophrenia in this population. Further research with larger sample sizes and consideration of gene-environment interactions is needed to provide deeper insights into the role of ACE in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.